Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report
Rationale: Collecting duct carcinoma (CDC) is a rare type of nonclear renal cell carcinoma, often presenting at an advanced stage of the disease, and standard treatment guidelines have not been established. Patient concerns: A 73-year-old man was admitted to our hospital with complaints of fever and lower right back pain. Diagnoses: Computed tomography revealed a poorly defined tumor of the right kidney without metastasis. The patient underwent right radical nephrectomy and was diagnosed with clinical stage T1bN0M0 renal cancer; the pathological findings showed collecting duct carcinoma. Interventions: After nephrectomy, multiple lung metastases were found in the following month, so first-line chemotherapy of gemcitabine (1000 mg/m2 on days 1 and 8, every 21 days) and cisplatin (70 mg/m2 on day 2, every 21 days) was administered. Due to disease progression, targeted therapy with axitinib (10 mg/body) and second-line chemotherapy of paclitaxel (200 mg/m2 on day 1, every 21 days) and carboplatin (area under the curve of 6 on day 1, every 21 days) were subsequently administered. However, the lung metastases progressed and new metastases spread to the right adrenal gland, liver, and lymph nodes. Based on the high expression of programmed death-ligand 1 in tumor cells, we treated the patient with the immune checkpoint inhibitor nivolumab. Outcomes: After 2 courses of treatment, he experienced a partial response and improved performance status, and thus was di...
Publication date: Available online 4 April 2020Source: Radiation Physics and ChemistryAuthor(s): B. Juste, R. Miró, S. Morató, G. Verdú, S. Peris
Publication date: Available online 4 April 2020Source: Radiation Physics and ChemistryAuthor(s): R.S. Omar, S. Hashim, S.K. Ghoshal, D.A. Bradley, N.D. Shariff
Publication date: Available online 5 April 2020Source: Journal of Molecular StructureAuthor(s): T. Valarmathi, R. Premkumar, A. Milton Franklin Benial
Publication date: Available online 4 April 2020Source: Redox BiologyAuthor(s): Raúl González, María A. Rodríguez-Hernández, María Negrete, Kalina Ranguelova, Aurelie Rossin, Carmen Choya-Foces, Patricia de la Cruz-Ojeda, Antonio Miranda-Vizuete, Antonio Martínez-Ruiz, Sergio Rius-Pérez, Juan Sastre, José A. Bárcena, Anne-Odile Hueber, C. Alicia Padilla, Jordi Muntané
Authors: Chen T, Gilfix B, Rivera JA, Sadeghi N, Richardson K, Hier MP, Forest VI, Fishman D, Caglar D, Pusztaszeri M, Mitmaker EJ, Payne RJ Abstract Though the current gold standard for diagnosing thyroid nodule malignancy is ultrasound-guided fine-needle aspiration (USFNA) cytology, about 20-25% of cytological evaluations are considered indeterminate for malignancy. This limitation has led to the emergence of next-generation sequencing panels, e.g. ThyroSeq v3 (TSv3), which recognize highly-diagnostic genetic mutations of common thyroid carcinomas in FNA samples and classifies them as test-negative or test-positi...
CONCLUSIONS: This study suggests that MTC is a more immunologically active tumor that has been previously reported. Patients with advanced MTC should be screened for targetable antigens and immune checkpoints to determine their eligibility for current clinical trials. Additional studies are necessary to fully characterize the antigenic potential of MTC and may encourage the development of adoptive T cells therapies for this rare tumor. PMID: 32242507 [PubMed - as supplied by publisher]
Authors: Brignardello-Petersen R PMID: 32245571 [PubMed - as supplied by publisher]
I'm a current fellow scheduled to graduate in July. After that, I'm joining a private practice located>1000 miles away from where I'm training. Until the pandemic hit, the plan was to fly out there next month to start looking for housing. In addition to the inherent risk of travel right now, my hospital just implemented a policy that if you leave the state you have to self-quarantine for 2 weeks (and they count that as vacation time). Not sure what I'm going to do to find housing in time... Finding housing during pandemic
Conclusion: there is no increased risk of doing the lymph node dissection early on. Dr. Eggener-CON Basics Lymph node dissections rarely done, even for large tumors, because there is no proven therapeutic or staging benefit for low risk patients. A Mayo study revealed no data showing therapeutic benefit in high risk patients. For clinically node negative high risk patients, there is staging value but no proven therapeutic benefit. Rate of positive nodes is associated with stage and grade; the higher the stage and grade, the more likely there will be positive nod...